Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Major Shareholder Cambrian Biopharma Inc Buys 9,202 Shares

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) major shareholder Cambrian Biopharma Inc purchased 9,202 shares of the stock in a transaction that occurred on Wednesday, January 12th. The stock was purchased at an average cost of $5.22 per share, with a total value of $48,034.44. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Cambrian Biopharma Inc also recently made the following trade(s):

  • On Wednesday, December 29th, Cambrian Biopharma Inc purchased 69,000 shares of Sensei Biotherapeutics stock. The shares were acquired at an average price of $4.98 per share, with a total value of $343,620.00.
  • On Monday, December 27th, Cambrian Biopharma Inc purchased 3,712 shares of Sensei Biotherapeutics stock. The shares were acquired at an average price of $5.30 per share, with a total value of $19,673.60.
  • On Thursday, December 16th, Cambrian Biopharma Inc purchased 10,925 shares of Sensei Biotherapeutics stock. The shares were acquired at an average price of $5.25 per share, with a total value of $57,356.25.

Shares of SNSE stock opened at $5.24 on Friday. Sensei Biotherapeutics, Inc. has a 12 month low of $4.70 and a 12 month high of $26.50. The stock has a 50 day moving average of $6.69 and a 200-day moving average of $8.15.

Sensei Biotherapeutics (NASDAQ:SNSE) last issued its quarterly earnings results on Monday, November 8th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.07). Equities analysts anticipate that Sensei Biotherapeutics, Inc. will post -1.37 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. American International Group Inc. raised its stake in shares of Sensei Biotherapeutics by 168.1% in the third quarter. American International Group Inc. now owns 11,437 shares of the company’s stock valued at $120,000 after purchasing an additional 7,171 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Sensei Biotherapeutics by 155.4% in the third quarter. Bank of New York Mellon Corp now owns 47,066 shares of the company’s stock valued at $495,000 after purchasing an additional 28,635 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Sensei Biotherapeutics in the third quarter valued at $113,000. Millennium Management LLC acquired a new position in shares of Sensei Biotherapeutics in the third quarter valued at $2,721,000. Finally, Royal Bank of Canada raised its stake in shares of Sensei Biotherapeutics by 255.1% in the third quarter. Royal Bank of Canada now owns 2,411 shares of the company’s stock valued at $25,000 after purchasing an additional 1,732 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc, a clinical-stage immunotherapy company, engages in the discovery and development of therapies with an initial focus on treatments for cancer. The company develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response.

Featured Article: What are no-load funds?

Insider Buying and Selling by Quarter for Sensei Biotherapeutics (NASDAQ:SNSE)

Receive News & Ratings for Sensei Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensei Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.